REG - Immupharma PLC - Director/PDMR Shareholding

ImmuPharmaAnnouncement

24/08/2021 11:10

RNS Number : 6189J
  
Immupharma PLC
  
24 August 2021
  
 

 
24 August 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
Director & PDMR Share Purchases 
 
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that each member of the Board of Directors and PDMR, Ewa Flynn (Chief Financial Officer) have on 23 & 24 August 2021 purchased in total 670,000 ordinary shares of 10p in the Company ("Ordinary Shares").
 
 
Details of the share purchases by the Board and their current interests in shares following the transactions are set out below.
 




NAME & TITLE


ORDINARY SHARES PURCHASED
& PURCHASE PRICE


NUMBER OF ORDINARY SHARES HELD POST TRANSACTION


% OF ISSUED SHARE CAPITAL 




Tim McCarthy
Chairman & Chief Executive Officer


250,000 @ 8.26p


288,462


0.12%




Dr Tim Franklin
Chief Operating Officer


125,000 @ 7.99p


125,000


0.05%




Dr Sanjeev Pandya
Senior Non-Executive Director


125,000 @ 8.00p


125,000
 


0.05%




Lisa Baderoon
Non-Executive Director & Head of Investor Relations 


140,000 @ 8.1957p


183,963


0.07%




Ewa Flynn
Chief Financial Officer &
Company Secretary


30,000 @ 7.892p


30,000


0.01%




 
 
Full disclosure of the transactions by persons discharging managerial responsibilities and persons closely associated with them ("PDMR's") are detailed at the end of the announcement. 
End
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended.  on publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
 
 
 
 
 




For further information please contact:
 




ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman and Chief Executive Officer


+ 44 (0) 207 152 4080




Dr Tim Franklin, Chief Operating Officer


 




Lisa Baderoon, Head of Investor Relations


+ 44 (0) 7721 413496
 
 




SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
 
Stanford Capital Partners (Joint Broker) 
Patrick Claridge
John Howes
Bob Pountney 
 
SI Capital (Joint Broker)
Nick Emerson
 


+44 (0) 203 368 3550
 
 
+44 (0) 203 815 8880
 
 
 
 
+44 (0) 1483 413500
 
 




4Reliance (Euronext Growth Listing Sponsor)
Jean-Charles Snoy
 
Degroof Petercam (Liquidity Provider)
Erik De Clippel
 
Backstage Communication
Olivier Duquaine
Gunther De Backer


+32 (0) 2 747 02 60
 
 
+32 (0) 2 287 95 34
 
 
 
+32 (0) 477 504 784
+32 (0) 475 903 909
 




 


 




 




Notes to Editors 
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US. 
For additional information about ImmuPharma please visit www.immupharma.co.uk 
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
 
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.




1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Tim McCarthy




2


Reason for the notification




a)


Position/status


Chairman and Chief Executive Officer 




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


On-market purchase




c)
 


Price(s) and volume(s)
 


Price


Volume




8.26p


250,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


 




e)


Date of the transaction


23 August 2021




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)




 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.




1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Dr Tim Franklin




2


Reason for the notification




a)


Position/status


Chief Operating Officer 




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


On-market purchase




c)
 


Price(s) and volume(s)
 


Price


Volume




7.99p


125,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


 




e)


Date of the transaction


24 August 2021




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)




 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.




1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Dr Sanjeev Pandya




2


Reason for the notification




a)


Position/status


Senior Non-Executive Director  




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


On-market purchase




c)
 


Price(s) and volume(s)
 


Price


Volume




8p


125,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


 




e)


Date of the transaction


23 August 2021




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)




 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.




1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Lisa Baderoon 




2


Reason for the notification




a)


Position/status


Non-Executive Director & Head of Investor Relations 




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


On-market purchase




c)
 


Price(s) and volume(s)
 


Price


Volume




8.1957p


140,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


 




e)


Date of the transaction


23 August 2021




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)




 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.




1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)


Name


Ewa Flynn




2


Reason for the notification




a)


Position/status


Chief Financial Officer (PDMR)




b)


Initial notification /Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


ImmuPharma PLC




b)


LEI


213800VZKGHXC7VUS895




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 


Ordinary Shares of 10p each
 
 
ISIN: GB0033711010




b)


Nature of the transaction


On-market purchase




c)
 


Price(s) and volume(s)
 


Price


Volume




7.892p


30,000




d)
 


Aggregated information
 
- Aggregated volume
 
- Price
 


 




e)


Date of the transaction


23 August 2021




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHPIMMTMTMTBAB